Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.60 |
| ▸ | DRD2 | P14416 | 18/20 | 0.60 |
| ▸ | HTR2C | P28335 | 3/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | DRD1 | P21728 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | DRD5 | P21918 | 2/20 | 0.60 |
| ▸ | HTR1D | P28221 | 2/20 | 0.60 |
| ▸ | HTR1B | P28222 | 2/20 | 0.60 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.60 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 12/20 | 0.55 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754907 | 1.00 | HTR2A (0.60) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL3754911 | 1.00 | HTR2A (0.60) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL28424510 | 0.89 | HTR2A (0.63) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL5261135 | 0.86 | DRD2 (0.58) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL5261132 | 0.86 | DRD2 (0.58) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL8027267 | 0.86 | DRD2 (0.58) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL8086351 | 0.84 | HTR2A (0.47) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL30523199 | 0.84 | HTR2A (0.62) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL6910347 | 0.84 | HTR2A (0.62) | HTR2ADRD2HTR2CADRA1AHRH1 | |
| SCHEMBL6853039 | 0.80 | HTR2A (0.58) | HTR2ADRD2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-8242269-B2 | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes | CIPLA LIMITED (IN) | 2012-08-14 | — | — | US | disclosed |
| US-8242269-B2 | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes | CIPLA LIMITED (IN) | 2012-08-14 | — | — | US | disclosed |
| US-20100298565-A1 | Processes for the Preparation of Paliperidone and Pharmaceutically Acceptable Salts Thereof and Intermediates for Use in the Processes | CIPLA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298565-A1 | Processes for the Preparation of Paliperidone and Pharmaceutically Acceptable Salts Thereof and Intermediates for Use in the Processes | CIPLA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2009047499-A2 | PROCESSES FOR THE PREPARATION OF PALIPERIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES FOR USE IN THE PROCESSES | CIPLA LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298565-A1 | Processes for the Preparation of Paliperidone and Pharmaceutically Acceptable Salts Thereof and Intermediates for Use in the Processes | AVPR2, AVPR1B, AVPR1A | HTR2A 1103/4885DRD2 1043/4885HTR2C 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.